Journal: Experimental and Therapeutic Medicine

Article Title: Oxaliplatin induces ferroptosis and oxidative stress in HT29 colorectal cancer cells by inhibiting the Nrf2 signaling pathway

doi: 10.3892/etm.2022.11321

Figure Lengend Snippet: Oxaliplatin inhibits the Nrf2 signaling pathway in colorectal cancer cells. Western blotting was performed to detect the levels of the Nrf2 signaling pathway-related proteins Nrf2, HO-1 and NQO1 in the control group and the groups treated with oxaliplatin concentrations of 1, 2 and 3 µM. Data are expressed as mean ± SD. * P<0.05, ** P<0.01, *** P<0.001. Nrf2, nuclear factor erythroid 2-related factor 2; HO-1, heme oxygenase-1; NQO1, NADPH dehydrogenase quinone 1.

Article Snippet: HT29 cells were cultured in serum-free medium overnight prior to treatment, after which time insulin was added to the medium for 15 min. Oxaliplatin at various concentrations (0.5, 1, 2 and 3 μM) was subsequently added to the medium for 72 h. A total of 200 μM Nrf2 activator, NK-252 (MedChemExpress) was then added to the medium to activate the Nrf2 pathway.

Techniques: Western Blot, Control

Journal: Experimental and Therapeutic Medicine

Article Title: Oxaliplatin induces ferroptosis and oxidative stress in HT29 colorectal cancer cells by inhibiting the Nrf2 signaling pathway

doi: 10.3892/etm.2022.11321

Figure Lengend Snippet: Oxaliplatin promotes ferroptosis and oxidative stress in colorectal cancer cells through inhibiting the Nrf2 signaling pathway. (A and B) Detection of relative total iron level and Fe 2+ level in HT29 cells was performed using an iron ion test kit in the control group and the groups treated with 3 µM of oxaliplatin as well as oxaliplatin (3 µM) + NK-252. (C and D) Western blotting was used to detect the levels of the ferroptosis-related proteins GPX4, FTH1 and transferrin in the control group and the groups treated with 3 µM of oxaliplatin as well as oxaliplatin (3 µM) + NK-252. (E-G) ELISA was used to detect the levels of the oxidative stress-related factors ROS, MDA and GSH in the control group and the groups treated with 3 µM of oxaliplatin as well as oxaliplatin (3 µM) + NK-252. Data are expressed as mean ± SD. * P<0.05, ** P<0.01, *** P<0.001. Nrf2, nuclear factor erythroid 2-related factor 2; GPX4, glutathione peroxidase 4; FTH1, ferritin heavy chain 1; ROS, reactive oxygen species; MDA, malondialdehyde; GSH, glutathione.

Article Snippet: HT29 cells were cultured in serum-free medium overnight prior to treatment, after which time insulin was added to the medium for 15 min. Oxaliplatin at various concentrations (0.5, 1, 2 and 3 μM) was subsequently added to the medium for 72 h. A total of 200 μM Nrf2 activator, NK-252 (MedChemExpress) was then added to the medium to activate the Nrf2 pathway.

Techniques: Control, Western Blot, Enzyme-linked Immunosorbent Assay